156 related articles for article (PubMed ID: 19833861)
21. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
[TBL] [Abstract][Full Text] [Related]
22. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
[TBL] [Abstract][Full Text] [Related]
23. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Philip G; van Adelsberg J; Loeys T; Liu N; Wong P; Lai E; Dass SB; Reiss TF
J Allergy Clin Immunol; 2009 Nov; 124(5):942-8.e1-9. PubMed ID: 19748656
[TBL] [Abstract][Full Text] [Related]
24. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
De Kam PJ; Luo WL; Wenning L; Ratcliffe L; Sisk CM; Royalty J; Radziszewski W; Wagner JA; Lai E
Platelets; 2014; 25(7):480-7. PubMed ID: 24206527
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
26. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
27. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Bays HE; Ballantyne C
Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
[TBL] [Abstract][Full Text] [Related]
28. Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Prescrire Int; 2010 Feb; 19(105):9-11. PubMed ID: 20455330
[TBL] [Abstract][Full Text] [Related]
29. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
30. A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients.
Yang YL; Hu M; Chang M; Tomlinson B
J Clin Pharm Ther; 2013 Dec; 38(6):528-32. PubMed ID: 24020480
[TBL] [Abstract][Full Text] [Related]
31. Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: laropiprant in comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosacea.
Krishna R; Guo Y; Schulz V; Cord-Cruz E; Smith S; Hair S; Nahm WK; Draelos ZD
J Clin Pharmacol; 2015 Feb; 55(2):137-43. PubMed ID: 25142778
[TBL] [Abstract][Full Text] [Related]
32. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
33. Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.
Song WL; Stubbe J; Ricciotti E; Alamuddin N; Ibrahim S; Crichton I; Prempeh M; Lawson JA; Wilensky RL; Rasmussen LM; Puré E; FitzGerald GA
J Clin Invest; 2012 Apr; 122(4):1459-68. PubMed ID: 22406532
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
35. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.
Philipose S; Konya V; Lazarevic M; Pasterk LM; Marsche G; Frank S; Peskar BA; Heinemann A; Schuligoi R
PLoS One; 2012; 7(8):e40222. PubMed ID: 22870195
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
Insull W; McGovern ME; Schrott H; Thompson P; Crouse JR; Zieve F; Corbelli J
Arch Intern Med; 2004 May; 164(10):1121-7. PubMed ID: 15159270
[TBL] [Abstract][Full Text] [Related]
37. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
Sorrentino SA; Besler C; Rohrer L; Meyer M; Heinrich K; Bahlmann FH; Mueller M; Horváth T; Doerries C; Heinemann M; Flemmer S; Markowski A; Manes C; Bahr MJ; Haller H; von Eckardstein A; Drexler H; Landmesser U
Circulation; 2010 Jan; 121(1):110-22. PubMed ID: 20026785
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
39. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
[TBL] [Abstract][Full Text] [Related]
40. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Schrör K; Löbel P; Steinhagen-Thiessen E
Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
